The global RWE solutions market is expected to grow at a CAGR of ~13.5% from 2021 to reach ~2.48 billion by 2027. The growth is primarily attributed to growing geriatric population, prevalence of chronic diseases, emphasis on value-based healthcare, increasing R&D investments, regulatory support and slow-paced drug development. However, factors such as lack of methodological standards and less trust real world studies can hinder the growth of this market. Rising focus on end-to-end real-world services and emerging markets offer significant growth opportunities. However, lack of organized data poses key challenge in this market.
By Component: Services segment registered largest share in 2020
Based on component, RWE solutions market is segmented into data sets and services. Services segment accounted for largest share of RWE solutions market in 2020. The large share of this segment can be mainly attributed to growing concern to pace up the drug development process, need for evidence from data and availability of huge healthcare data.
By Therapeutic Area: Oncology segment dominated the market in 2020
Based on therapeutic area, RWE solutions market is segmented into oncology, cardiovascular, neurology, immunology and others. Oncology segment leaded the RWE solutions market by share. The large market share is mainly ascribed by increasing number of clinical trials and growing prevalence of cancer across globe.
By End User: Pharmaceutical & medical device companies segment dominate the RWE solutions market
By end user, RWE solutions market is segmented into pharmaceutical & medical devices companies, healthcare providers, healthcare payers, and other end users. Pharmaceutical & medical device companies segment accounted for largest share of the RWE solutions market, by end user in 2020. The large share is mainly attributed to significance of RWE studies in drug approval process, growing need to prevent drug recalls, and usefulness of drug performance data in real-world setting.
By Region: North America expected to dominate the regional market
North America is expected to dominate the RWE solutions market by region. The large share is primarily attributed to regulatory support, growing number of payers, increasing RWE service providers and growing adoption of RWE by pharmaceutical companies in North America region. APAC is expected to register highest CAGR. The growth can be attributed to government initiatives, prevalence of chronic diseases, increasing geriatric population and emphasis on improving healthcare services.
Competitive Scenario
- IQVIA (US)
- IBM (US)
- ICON plc. (Ireland)
- PAREXEL International Corporation (US)
- PPD, LLC (US)
- Optum Inc. (US)
- Cognizant (US)
- Oracle (US)
- SAS (US)
- Syneos (US)
- Anthem (US)
- Clinigen (UK)
- PerkinElmer (US)
- Cerner Corporation (US)
- Medpace (US)
- Aetion (US)
- Cegedim Health Data (France)
- TriNetX (US)
- Trinity (US)
- Verantos (US)
- Sciformix (US)
- Ciox Health (US)
- Tempus (US)
- Flatiron Health (US)
- And Syapse (US)
are the key players operating in this market.
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. COVID-19 Impact of the RWE solutions Market
5. Industry Insights
5.1. Introduction
5.2. Industry Trends
6. Global RWE solutions Market, By Component, 2019-2027 (USD Million)
6.1. Services
6.2. Data sets
6.2.1. Clinical setting data
6.2.2. Claims data
6.2.3. Pharmacy data
6.2.4. Patient powered data
7. Global RWE solutions Market, By Therapeutic area, 2019-2027 (USD Million)
7.1. Oncology
7.2. Cardiovascular
7.3. Neurology
7.4. Immunology
7.5. Others
8. Global RWE solutions Market, By End User, 2019-2027 (USD Million)
8.1. Pharmaceutical & Medical devices companies
8.2. Healthcare providers
8.3. Healthcare payers
8.4. Other End Users
9. Global RWE solutions Market, By Geography, 2019-2027 (USD Million)
9.1. North America
9.1.1. US
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. UK
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. Rest of Asia-Pacific
9.4. Rest of the World
9.4.1. Latin America
9.4.2. Middle East & Africa
10. Competitive Landscape
10.1. Introduction
10.2. Market Ranking Analysis, By Key Players (2020)
10.3. Competitive Situation and Trends
10.3.1. Product Launches
10.3.2. Partnerships, Collaborations and Agreements
10.3.3. Acquisitions
10.3.4. Expansions
10.3.5. Other Developments
11. Company Profiles
11.1. IQVIA (US)
11.2. IBM (US)
11.3. ICON, plc. (Ireland)
11.4. PAREXEL International Corporation (US)
11.5. PPD, LLC (US)
11.6. Optum, Inc. (US)
11.7. Cognizant (US)
11.8. Oracle (US)
11.9. SAS (US)
11.10. Syneos (US)
11.11. Anthem (US)
11.12. Clinigen (UK)
11.13. PerkinElmer (US)
11.14. Cerner Corporation (US)
11.15. Medpace (US)
11.16. Aetion (US)
11.17. Cegedim Health Data (France)
11.18. TriNetX (US)
11.19. Trinity (US)
11.20. Verantos (US)
11.21. Sciformix (US)
11.22. Ciox Health (US)
11.23. Tempus (US)
11.24. Flatiron Health (US)
11.25. Syapse (US)
12. Appendix
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
